Site Search:

Home

Outsourcing Reports

Outsourcing Showcase

Reports Store

Outsourcing Directory

Events

Advertising

News

11 Items, CDN $ 9921

Go Back

Booming Pharma Sector in India RNCOS August 2008 Report Code: RNCOSBP CDN $ 1100 Buy Abstract 100 Pages "India, a US$ 8.2 Billion pharmaceutical market, represents one of the most emerging pharmaceutical markets in the world. According to the RNCOS latest report “Booming Pharma Sector in India”, in near future, the potential and opportunities within this market will increase by several folds. The market, presently driven by over a billion population, an expanding GDP, and rapid epidemiological transitions, is expected to be the major player in the global pharmaceutical market both in terms of its large domestic market and also as a pharmaceutical export hub. The research study contains unique market-based research and provides detailed and objective analysis on the Indian pharmaceutical market. It presents a thorough statistical and analytical overview on the Indian pharmaceutical market, and provides past, present and future data on the entire structure, composition and working of the Indian pharmaceutical market. The research extensively discusses the opportunities and challenges that are expected to arise within and from the pharmaceutical market. Research Highlights § Between 2007-08 and 2011-12, the Indian domestic pharmaceutical market is expected to grow at a CAGR of nearly 16%. § The size of the domestic pharmaceutical market is larger than export market. However, owing to the growth of global generics market, stringent price controls in the domestic market, and better margins, the export market is growing much faster than the domestic market. § Traditional branded generics presently dominate the Indian pharmaceutical market but the future will see strong growth in the specialty branded generics and patented drug segments. § Drugs for diabetes and cardiovascular diseases are expected to see the fastest growth among all therapy areas during 2007-2011. § The retail pharmaceutical market in India is presently highly unorganized; however, a vast opportunity exists for the organized market. § Over the last few years, Cipla, Ranbaxy and GlaxoSmithKline are controlling the top three positions in the Indian pharmaceutical market. The Report Covers § Analysis of past, current and future market trends. § Market study by segment. § Discussion about the major drivers of the pharmaceutical market. § Analysis of opportunities created by the market. § Evaluation of major challenges for the market. § Review on the government regulations. § Competitive landscape of the market. Research Methodology Used Information Sources Information has been sourced from books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases. Analysis Methods The analysis methods include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis." Table of Contents "1. Analyst View 2. Global Pharmaceutical Market 3. India - The Emerging Market 4. India - Macroeconomic & Healthcare Profile 4.1 Macroeconomic Profile 4.2 Population Profile 4.3 Healthcare Profile 5. Indian Pharmaceutical Market 5.1 Turnover 5.2 Trade 5.2.1 Export 5.2.2 Import 5.3 Bulk Drugs & Formulations 6. Domestic Pharmaceutical Market 6.1 What Makes the Market so Lucrative? 6.1.1 Ageing Population 6.1.2 Increasing Income 6.1.3 Product Patent Regime 6.1.4 Medical Infrastructure 6.1.5 Prevalence of Lifestyle-related Diseases 6.2 Market Size 6.3 Market Segmentation 6.3.1 By Drugs 6.3.1.1 Traditional Branded Generics 6.3.1.2 Specialty Branded Generics 6.3.1.3 Generic Generics 6.3.1.4 Patented Drugs 6.3.2 By Therapeutics 6.3.2.1 Acute Segment 6.3.2.1.1 Anti-infectives 6.3.2.1.2 Gastrointestinal 6.3.2.1.3 Vitamins/Minerals/Nutrients 6.3.2.1.4 Pain/Analgesics 6.3.2.1.5 Dermatology 6.3.2.1.6 Gynecology 6.3.2.1.7 Respiratory 6.3.2.2 Chronic Segment 6.3.2.2.1 Cardiac 6.3.2.2.2 Neuro/CNS 6.3.2.2.3 Anti-diabetic 6.4 Market Structure 6.5 Key Players 6.6 Future Outlook 6.6.1 Market Drivers & Restraints 6.6.2 Sales (2008-09 to 2011-12) 7. Government Regulations & Market Entry 7.1 Industrial & Manufacturing License 7.2 Patent Laws 7.3 Research & Development 7.4 Pricing 7.5 Market Entry 8. Opportunities 8.1 Biogenerics 8.2 Rural Markets 8.3 Pharma Outsourcing Market 8.4 Bioinformatics 8.5 Health Insurance 8.6 Drug Delivery & Packaging Industry 8.7 Pharmaceutical Retail Chains 9. Roadblocks 9.1 Lack of Innovation 9.2 Drug Price Controls & Low Margins 9.3 Low Per Capita Spending on Drugs 9.4 Multinationals Reluctant to Invest in India 9.5 Counterfeit Drugs 9.6 Government Financing 10. Profile of Key Players 10.1 Ranbaxy Laboratories Limited 10.2 Cipla Limited 10.3 GlaxoSmithKline Pharmaceuticals Limited 10.4 Nicholas Piramal India Limited 10.5 Zydus Cadila"

Using the Site   Privacy & Security Statement
Advertise with us   Directory Guide
CanBiotech Newsletters

© 2000-2010 CanBiotech™ Inc.